We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,674 | 01:00:00 |
By Marc Bisbal Arias
Novartis AG (NOVN.EB) said Wednesday that it has signed an alliance with the Bill & Melinda Gates Foundation for further development of a drug that treats the diarrheal disease cryptosporidiosis.
The Swiss company said that the Gates Foundation will provide $6.5 million to support the development of Novartis's drug candidate KDU731.
"Cryptosporidiosis is the second leading cause of infectious diarrhea in children under two years of age," Novartis said. Diarrheal diseases cause around 525,000 deaths a year.
Write to Marc Bisbal Arias at marc.bisbalarias@dowjones.com
(END) Dow Jones Newswires
February 14, 2018 01:49 ET (06:49 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions